Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS

Changes in Beneficial Ownership · 4

BioStem Technologies, Inc.

BSEMNASDAQEQUITYCurrent

Changes in Beneficial Ownership

Filed Nov 19, 2026Accepted Nov 19, 2026, 4:30 PM ESTFiling CIK 1658678Accession 0001193125-26-468654
Share

Structured filing — 4

ownership.xml

Open full document ↗

Filing details

Report period
2026-11-17
Issuer
BioStem Technologies, Inc.
Issuer CIK
0001658678
Trading symbol
BSEM

Reporting owner 1

Name
Matuszewski Jason
Reporting owner CIK
0001634730
Relationship
Director · Officer · 10% owner
Officer title
Chief Executive Officer
Address
C/O BIOSTEM TECHNOLOGIES, INC., 2836 CENTER PORT CIRCLE, POMPANO BEACH, FL, 33064

Non-derivative transactions

Non-derivative transactions · 1 reported row
SecurityTransaction dateCodeAmountA / DPrice (USD)Owned afterOwnership
Common Stock2026-11-17S · Form 4[F1]14,300D1.001,539,251D
Table key
S · Form 4
Sale on the market or privately
D
Direct

Derivative holdings

Derivative holdings · 8 reported rows
SecurityConversion / exercise price (USD)ExercisableExpiresUnderlying securityUnderlying sharesAmount ownedOwnership
Series A-1 Convertible Preferred Shares[F2]2016-05-23[F3]Common Stock100100D
Options (Right to Buy)2.00[F4]2032-10-24Common Stock2,000,0002,000,000D
Options (Right to Buy)10.05[F5]2035-03-17Common Stock198,807198,807D
Options (Right to Buy)10.05[F6]2035-10-13Common Stock40,42740,427D
Options (Right to Buy)5.50[F7]2036-02-11Common Stock440,529440,529D
Restricted Stock Units[F8][F9][F9]Common Stock33,87433,874D
Restricted Stock Units[F8][F10][F10]Common Stock99,90199,901D
Restricted Stock Units[F8][F11][F11]Common Stock363,636363,636D
Table key
D
Direct

Footnotes

F1
Represents shares sold to cover the Reporting Person's tax obligation in connection with the exercise of vested options to purchase shares of the Issuer's Common Stock.↩ 1
F2
The Series A-1 Preferred Convertible Stock is convertible in whole into shares of the Issuer's Common Stock on a one-to-one basis at the option of a majority of the holders of Series A-1 Preferred Stock.↩ 1
F3
The Series A-1 Preferred Convertible Stock has no expiration date.↩ 1
F4
These options are fully vested and exercisable.↩ 1
F5
These options vest according to the following schedule: 33% vested on March 17, 2026, the one-year anniversary of the grant date, with the remaining options vesting in equal quarterly installments over the subsequent two year period.↩ 1
F6
These options vest according to the following schedule: 33% vested on October 13, 2026, the one year anniversary of the grant date, with the remaining options vesting in equal quarterly installments over the subsequent two year period.↩ 1
F7
These options vest according to the following schedule: 33% will vest on February 11, 2027, the one year anniversary of the grant date, with the remaining options vesting in equal quarterly installments over the subsequent two year period.↩ 1
F8
Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.↩ 1↩ 2↩ 3
F9
These restricted stock units vest in equal quarterly installments over three year from the grant date (September 15, 2024).↩ 1↩ 2
F10
These restricted stock units vest according to the following schedule: 33% vested on March 17, 2026, the one year anniversary of the grant date, with the remaining units vesting in equal quarterly installments over the subsequent two year period.↩ 1↩ 2
F11
These restricted stock units vest according to the following schedule: 33% will vest on February 11, 2027, the one year anniversary of the grant date, with the remaining units vesting in equal quarterly installments over the subsequent two year period.↩ 1↩ 2

Signature 1

Signed
/s/ Katherine Gorrell, Attorney-in-Fact
Date
2026-11-19

Company context

BioStem Technologies, Inc. is a publicly traded, biomedical innovator, focused on developing, manufacturing and commercializing advanced allograft solutions derived from perinatal tissue. The company leverages its industry-leading proprietary BioRetain®, CryoTek® and SteriTek® processing technologies, designed to optimize the preservation of the natural properties of these tissues, supporting their use in clinical settings. Its allografts are used by clinicians across a wide range of specialties. With a growing portfolio of products, expanding clinical research initiatives, and a national commercial footprint, BioStem is committed to advancing innovation in regenerative medicine.

Current securities

Historical securities (5)

Recent company filings

  1. 424B3 filingNov 19, 2026
  2. 424B3 filingNov 19, 2026
  3. 424B3 filingNov 19, 2026
  4. 10-Q filingNov 12, 2026
  5. Results of Operations and Financial ConditionNov 12, 2026

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.